Lazertinib

Chemical formula: C₃₀H₃₄N₈O₃  Molecular mass: 554.275 g/mol  PubChem compound: 121269225

Therapeutic indications

Lazertinib is indicated for:

First-line treatment of advanced non-small cell lung cancer with EGFR mutations in combination with amivantamab

Population group: only adults (18 years old or older)

Lazertinib in combination with amivantamab is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lazertinib is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: LAZCLUZE Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈